{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"1.4","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"815.2","value":"2.1"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"0.7","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}],"units":"Blood samples"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0.6","value":"0.3"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"8.4","value":"0"},{"groupId":"OG002","lowerLimit":"0.8","upperLimit":"9276.0","value":"838.4"},{"groupId":"OG003","lowerLimit":"297.8","upperLimit":"1982.4","value":"608.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}],"units":"Blood samples"}],"title":"Day 29"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"1.2","value":"0.6"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"6.3","value":"0"},{"groupId":"OG002","lowerLimit":"1.8","upperLimit":"29849.1","value":"10830.2"},{"groupId":"OG003","lowerLimit":"26558.4","upperLimit":"40941.6","value":"35863.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}],"units":"Blood samples"}],"title":"Day 36"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.2","upperLimit":"40.7","value":"40.0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"8.0","value":"0.23"},{"groupId":"OG002","lowerLimit":"0.6","upperLimit":"32795.2","value":"23084.7"},{"groupId":"OG003","lowerLimit":"20401","upperLimit":"38429.7","value":"27319.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}],"units":"Blood samples"}],"title":"Day 57"},{"categories":[{"measurements":[{"comment":"One out of two participants provided a sample, which was included for analysis. The other participant was not analyzed and moved to the booster cohort, so this timepoint was censored.","groupId":"OG000","lowerLimit":"NA","upperLimit":"53156.4","value":"53156.4"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"107.4","value":"53.7"},{"groupId":"OG002","lowerLimit":"23639.6","upperLimit":"28668.2","value":"26153.9"},{"groupId":"OG003","lowerLimit":"2467.1","upperLimit":"4041.3","value":"3198.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}],"units":"Blood samples"}],"title":"Day 209"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"20779.1","upperLimit":"33967.9","value":"24665.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}],"units":"Blood samples"}],"title":"Day 394"}],"denomUnitsSelected":"Blood samples","denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"42"},{"groupId":"OG003","value":"15"}],"units":"Blood samples"}],"description":"Immunogenicity of mRNA 1273 administered in 2 doses was assessed by titer or level of specific binding antibody (bAb), in participants who have a hematological malignancy and are immunosuppressed due to their disease and/or treatment or receiving a programmed death-1 (PD-1)/programmed death-ligand 1 inhibitor for treatment of a solid tumor - Titer or level of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific binding antibody (bAb) measured by enzyme-linked immunosorbent assay (ELISA) on Day 1, Day 29, Day 36, Day 57, Day 209, and Day 394.","dispersionType":"Full Range","groups":[{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on days 1 and 29; with option for subsequent booster dose, 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29.","id":"OG000","title":"Hematologic Low Immunosuppression - Initial Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on days 1 and 29; with option for subsequent booster dose, 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29.","id":"OG001","title":"Hematologic Intermediate Immunosuppression - Initial Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on days 1 and 29; with option for subsequent booster dose, 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29","id":"OG002","title":"Hematologic High Immunosuppression - Initial Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on days 1 and 29; with option for subsequent booster dose, 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29.","id":"OG003","title":"Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase"}],"paramType":"MEDIAN","populationDescription":"Day 394 Groups 1, 2 and 4 respectively; no participants reached this timepoint to be analyzed because, 1) the follow up was too short for participants and/or participants crossed over to the booster cohort.","reportingStatus":"POSTED","timeFrame":"Day 1, Day 29, Day 36, Day 57, Day 209, and Day 394","title":"Immunogenicity of Messenger Ribonucleic Acid (mRNA) Titers - 1273 Administered in 2 Doses in the Initial Phase","type":"PRIMARY","typeUnitsAnalyzed":"Blood samples","unitOfMeasure":"Au/mL"}